Vered Klinghofer

3.0k citations

27 papers · 1.3k indexed · h-index 21

Co-authors: Vincent L. Giranda Jennifer S. Pollock Xuesong Liu Eric F. Johnson Ulrich Förstermann Gui‐Dong Zhu Thomas D. Penning Saul H. Rosenberg
Topics: Nitric Oxide and Endothelin Effects (5 papers)PI3K/AKT/mTOR signaling in cancer (5 papers)Peptidase Inhibition and Analysis (5 papers)
Cited by: Biochemistry Organic Chemistry Oncology
Journals: Science Journal of Molecular Biology Biochemistry
Partner nations: United States United Kingdom Canada

In The Last Decade

Vered Klinghofer

27 papers receiving 1.2k citations

Peers

Countries citing papers authored by Vered Klinghofer

Since Specialization

Citations

This map shows the geographic impact of Vered Klinghofer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vered Klinghofer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vered Klinghofer more than expected).

Fields of papers citing papers by Vered Klinghofer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vered Klinghofer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vered Klinghofer. The network helps show where Vered Klinghofer may publish in the future.

Co-authorship network of co-authors of Vered Klinghofer

This figure shows the co-authorship network connecting the top 25 collaborators of Vered Klinghofer. A scholar is included among the top collaborators of Vered Klinghofer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vered Klinghofer. Vered Klinghofer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·Qingwei Zhang,(unknown),Michael J. Mitten,Loren Lasko,Vered Klinghofer,Jennifer J. Bouska,Eric F. Johnson,Thomas D. Penning,Yan Luo,Vincent L. Giranda,Alexander R. Shoemaker,Kent D. Stewart,Stevan W. Djurić,Anil Vasudevan	12
2	Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer 2009 ·Bioorganic & Medicinal Chemistry Letters ·Viraj B. Gandhi,Yan Luo,Xuesong Liu,Yan Shi,Vered Klinghofer,Eric F. Johnson,Chang Park,Vincent L. Giranda,Thomas D. Penning,Gui‐Dong Zhu	29
3	Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: Chemistry, biological activities, and molecular modeling 2008 ·Bioorganic & Medicinal Chemistry Letters ·Yunsong Tong,Kent D. Stewart,Sheela A. Thomas,(unknown),Eric F. Johnson,Vered Klinghofer,Joel Johansson,(unknown),Niru B. Soni,Yan Luo,Nan‐Horng Lin,Thomas J. Sowin,Vincent L. Giranda,Thomas D. Penning	52
4	Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks 2008 ·Molecular Cancer Research ·Xuesong Liu,Yan Shi,Ran Guan,Cherrie K. Donawho,Yanping Luo,Joann P. Palma,Gui‐Dong Zhu,Eric F. Johnson,Luis E. Rodrı́guez,Nayereh Ghoreishi‐Haack,Ken Jarvis,Vincent P. Hradil,Milagros Colon-Lopez,Bryan F. Cox,Vered Klinghofer,Thomas D. Penning,Saul H. Rosenberg,David J. Frost,Vincent L. Giranda,Yan Luo	61
5	Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent 2008 ·Bioorganic & Medicinal Chemistry Letters ·Gui‐Dong Zhu,Viraj B. Gandhi,Jianchun Gong,Sheela A. Thomas,Yan Luo,Xuesong Liu,Yan Shi,Vered Klinghofer,Eric F. Johnson,David J. Frost,Cherrie K. Donawho,Ken Jarvis,Jennifer J. Bouska,Kennan C. Marsh,Saul H. Rosenberg,Vincent L. Giranda,Thomas D. Penning	42
6	Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt 2007 ·Bioorganic & Medicinal Chemistry ·Gui‐Dong Zhu,Jianchun Gong,Viraj B. Gandhi,Keith W. Woods,Yan Luo,Xuesong Liu,Ran Guan,Vered Klinghofer,Eric F. Johnson,Vincent S. Stoll,Mulugeta Mamo,Qun Li,Saul H. Rosenberg,Vincent L. Giranda	58
7	Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers 2006 ·Bioorganic & Medicinal Chemistry Letters ·Gui‐Dong Zhu,Viraj B. Gandhi,Jianchun Gong,Yan Luo,Xuesong Liu,Yan Shi,Ran Guan,(unknown),Vered Klinghofer,Eric F. Johnson,Jennifer J. Bouska,Alexander R. Shoemaker,Anatol Oleksijew,Ken Jarvis,Chang Park,Ron de Jong,Tilman Oltersdorf,Qun Li,Saul H. Rosenberg,Vincent L. Giranda	42
8	Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase 2006 ·Bioorganic & Medicinal Chemistry Letters ·Sheela A. Thomas,Tongmei Li,Keith W. Woods,Xiaohong Song,Garrick K. Packard,John P. Fischer,R. Bruce Diebold,Xuesong Liu,Yan Shi,Vered Klinghofer,Eric F. Johnson,Jennifer J. Bouska,Amanda M. Olson,Ran Guan,(unknown),Kennan Marsh,Yan Luo,Saul H. Rosenberg,Vincent L. Giranda,Qun Li	11
9	Optimal Classes of Chemotherapeutic Agents Sensitized by Specific Small-Molecule Inhibitors of Akt In Vitro and In Vivo 2005 ·Neoplasia ·Yan Shi,Xuesong Liu,Edward K. Han,Ran Guan,Alexander R. Shoemaker,Anatol Oleksijew,Keith W. Woods,John P. Fisher,Vered Klinghofer,Loren Lasko,Thomas McGonigal,Qun Li,Saul H. Rosenberg,Vincent L. Giranda,Yan Luo	35
10	Interaction with the S1β-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Michael Wendt,(unknown),William J. McClellan,Todd W. Rockway,Moshe Weitzberg,(unknown),Robert A. Mantei,Kent D. Stewart,V. Nienaber,Vered Klinghofer,Vincent L. Giranda	24
11	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties 2004 ·Bioorganic & Medicinal Chemistry Letters ·Milan Bruncko,William J. McClellan,Michael Wendt,Daryl R. Sauer,(unknown),(unknown),(unknown),Moshe Weitzberg,(unknown),Joseph F. Dellaria,Robert A. Mantei,(unknown),V. Nienaber,Kent D. Stewart,Vered Klinghofer,Jennifer B. Bouska,Todd W. Rockway,Vincent L. Giranda	19
12	Pseudosubstrate Peptides Inhibit Akt and Induce Cell Growth Inhibition 2004 ·Biochemistry ·Yan Luo,Richard A. Smith,Ran Guan,Xuesong Liu,Vered Klinghofer,Jianwei Shen,Charles W. Hutchins,Paul Richardson,(unknown),Saul H. Rosenberg,Vincent L. Giranda	44
13	Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite 2000 ·Structure ·V. Nienaber,Donald J. Davidson,Rohinton Edalji,Vincent L. Giranda,Vered Klinghofer,Jack Henkin,(unknown),Robert A. Mantei,(unknown),Jean M. Severin,Richard A. Smith,Kent D. Stewart,Karl A. Walter,Jieyi Wang,Michael Wendt,Moshe Weitzberg,(unknown),Todd W. Rockway	46
14	Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry 1998 ·Bioorganic & Medicinal Chemistry Letters ·Kent D. Stewart,Stefan Loren,Lisa Frey,(unknown),Vered Klinghofer,Keren I. Hulkower	25
15	Novel potent and selective inhibitors of inducible nitric oxide synthase. 1995 ·Molecular Pharmacology ·Masaki Nakane,Vered Klinghofer,Jane Kuk,(unknown),Gerald P. Budzik,Jennifer S. Pollock,Fatima Z. Basha,(unknown)	112
16	The nitric oxide synthase inhibitor, L-NG-monomethylarginine, reduces carrageenan-induced pleurisy in the rat. 1995 ·Journal of Pharmacology and Experimental Therapeutics ·W. Ross Tracey,(unknown),Jane Kuk,Gerald P. Budzik,Vered Klinghofer,Richard Harris,(unknown)	71
17	Functional Expression of Three Isoforms of Human Nitric Oxide Synthase in Baculovirus-Infected Insect Cells 1995 ·Biochemical and Biophysical Research Communications ·Masaki Nakane,Jennifer S. Pollock,Vered Klinghofer,Fatima Z. Basha,Philip A. Marsden,Atsushi Hokari,T. Ogura,Hiroyasu Esumi,(unknown)	34
18	Nonpeptide Renin Inhibitors with Good Intraduodenal Bioavailability and Efficacy in Dog 1994 ·Journal of Medicinal Chemistry ·Steven A. Boyd,Anthony K. L. Fung,William R. Baker,Robert A. Mantei,Herman H. Stein,Jerome D. Cohen,(unknown),Vered Klinghofer,Jerry L. Wessale	29
19	Cardiovascular Effects and Hemodynamic Mechanism of Action of the Novel, Nonpeptidic Renin Inhibitor A-74273 in Dogs 1993 ·Journal of Cardiovascular Pharmacology ·Jerry L. Wessale,Samuel V. Calzadilla,Steven A. Boyd,William R. Baker,Herman H. Stein,Peter Kovar,(unknown),Vered Klinghofer,Robert A. Mantei,Hollis D. Kleinert	8
20	Effects of High Doses of A-74273, a Novel Nonpeptidic and Orally Bioavailable Renin Inhibitor 1993 ·Journal of Cardiovascular Pharmacology ·Kenneth M. Verburg,James S. Polakowski,Peter Kovar,Vered Klinghofer,(unknown),Herman H. Stein,Robert A. Mantei,Anthony K. L. Fung,Steven A. Boyd,William R. Baker,Hollis D. Kleinert	8

About Vered Klinghofer

Vered Klinghofer is a scholar working on Oncology, Cancer Research and Genetics, having authored 27 papers that have together received 1.3k indexed citations. Recurring topics across this work include Nitric Oxide and Endothelin Effects (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Biochemistry (97 citations), Organic Chemistry (372 citations) and Oncology (338 citations). Vered Klinghofer has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Vincent L. Giranda, Jennifer S. Pollock, Xuesong Liu, Eric F. Johnson, Ulrich Förstermann, Gui‐Dong Zhu, Thomas D. Penning, Saul H. Rosenberg, Gerald P. Budzik and Viraj B. Gandhi. Their work appears in journals such as Science, Journal of Molecular Biology and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact